Alnaimat Fatima, Alduraidi Hamza, Yaghi Ali Rezeq Ali, Tarbiah Mohammad Mahmoud, Khanfar Asim, Abusheikha Moath, Hamad Ali M
Department of Internal Medicine, Division of Rheumatology/ School of Medicine -University of Jordan, Amman, Jordan.
School of Nursing, The University of Jordan, Amman, Jordan.
PLoS One. 2025 Jul 3;20(7):e0327436. doi: 10.1371/journal.pone.0327436. eCollection 2025.
Chronic glucocorticoid (GC) therapy is common in patients with rheumatic medical diseases (RMD). However, long-term use of GCs can be associated with significant adverse effects. This study aims to determine the prevalence of GC use among patients with RMD and understand their perceptions of GC use and safety. This cross-sectional survey was conducted at a tertiary academic university hospital in Amman, Jordan. RMD patients were anonymously approached while awaiting rheumatology clinic appointments. Convenience sampling was employed, with enrollment taking place between January and September 2021. Of 500 participants, 315 (63%) reported current (171/315, 54.3%) or past (144/315, 45.7%) use of GCs, primarily prescribed for RMD (267/315, 84.7%). Most (270/315, 85.7%) used GCs orally, with the majority taking them daily (266/315, 84.4%). A small percentage (33/315, 10.5%) used GCs only as needed. Long-term use was common, with 57.8% (182/315) reporting use for years and 84.1% (265/315) adhering to doctor recommendations. Perception-wise, 69.5% (219/315) of GC users believed in its efficacy, whereas 78.7% (248/315) considered it unsafe, compared to 51.9% (96/185) of non-users. Awareness of side effects was higher among GC users (219/315, 69.5%) than non-users (79/185, 42.7%), with weight gain being the most reported side effect. Media and personal research were the primary information sources for GC users (193/315, 61.3%). Side effects were reported by 110/315 (34.9%) GC users, with weight gain as the most common (47%). Both perceived efficacy and safety of GC were positively and significantly correlated with educational level (p = .005, p = .000, respectively) and monthly income (p = .044, p = .000, respectively). GC use is prevalent among Jordanian patients with RMDs, with perceptions of efficacy and safety strongly influenced by education and income. Enhanced patient education on the side effects of GC is crucial for improving treatment adherence and outcomes.
慢性糖皮质激素(GC)治疗在风湿性疾病(RMD)患者中很常见。然而,长期使用GC可能会带来显著的不良反应。本研究旨在确定RMD患者中GC的使用 prevalence,并了解他们对GC使用和安全性的看法。这项横断面调查在约旦安曼的一家三级学术大学医院进行。在RMD患者等待风湿病门诊预约时,以匿名方式与他们接触。采用便利抽样,招募时间为2021年1月至9月。在500名参与者中,315名(63%)报告目前(171/315,54.3%)或过去(144/315,45.7%)使用过GC,主要用于RMD的处方(267/315,84.7%)。大多数(270/315,85.7%)口服GC,大多数人每天服用(266/315,84.4%)。一小部分(33/315,10.5%)仅根据需要使用GC。长期使用很常见,57.8%(182/315)报告使用了数年,84.1%(265/315)遵循医生建议。从认知角度来看,69.5%(219/315)的GC使用者相信其疗效,而78.7%(248/315)认为其不安全,相比之下,非使用者为51.9%(96/185)。GC使用者对副作用的知晓率(219/315,69.5%)高于非使用者(79/185,42.7%),体重增加是报告最多的副作用。媒体和个人研究是GC使用者的主要信息来源(193/315,61.3%)。110/315(34.9%)的GC使用者报告有副作用,体重增加最为常见(47%)。GC的感知疗效和安全性均与教育水平(分别为p = 0.005,p = 0.000)和月收入(分别为p = 0.044,p = 0.000)呈正相关且显著相关。GC在约旦RMD患者中使用普遍,疗效和安全性的认知受教育和收入的强烈影响。加强患者对GC副作用的教育对于提高治疗依从性和治疗效果至关重要。